Issued on behalf of Avant Technologies
Inc.
Equity Insider News Commentary
VANCOUVER, BC, June 10,
2025 /PRNewswire/ -- Both politicians and leaders in
academia are touting the AI revolution empowering the frontline of
what's dubbed Smart Healthcare. In a recent write-up in
Forbes, Prof. Nicos Savva of
the London Business School cited
recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to
embrace a future with AI doctors and nurses, or risk being left
behind. A new report from Wolters
Kluwer has experts calling for more clarity around its
use, adoption, and business strategy, because most healthcare
organizations aren't currently ready to use GenAI tools. But as
implementations increase across the sector, so too are major
developments coming from innovators, including Avant
Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ:
RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL),
Omada Health, Inc. (NASDAQ: OMDA), and Amazon.com,
Inc. (NASDAQ: AMZN).
McKinsey's Global Institute estimates Gen AI could unlock
$60–110 billion in annual value across pharma and medical products
alone. Statista now projects the global AI healthcare market
will soar from $11 billion to
$188 billion by 2030.
Avant Technologies, Inc. (OTCQB: AVAI) has just
taken a major step forward in its evolution from AI incubator to
full-stack healthcare innovator. Today, the company announced it
had signed a non-binding letter of intent to acquire 100% of
Ainnova Tech, its joint venture partner and the developer of
the Vision AI diagnostic platform. Prior to the acquisition, the
two companies have been operating jointly through Ai-nova
Acquisition Corp (AAC), which holds global licensing rights to
Ainnova's technology portfolio and serves as the
commercialization engine for Vision AI and all future device
deployments.
"We believe bringing the two companies together will offer
tremendous value for shareholders, it will simplify the process of
advancing our technology to market, and it will deliver value to
our customers and partners as we promote our technology portfolio
globally," said Vinicio Vargas, CEO
at Ainnova and a member of the Board of Directors of
AAC. "We feel the joint venture has been a success and both
companies have worked well together toward a common goal, so we
believe that we can be even more successful and use our resources
more effectively as one company to further AI in healthcare."
Under the proposed agreement, Ainnova would roll all of
its outstanding equity into the combined public entity — unifying
leadership and eliminating structural complexity ahead of a
scheduled FDA pre-submission meeting in July.
While final terms of the deal are still being negotiated, both
companies say the merger would streamline commercialization and
accelerate the rollout of Ainnova's flagship Vision AI
technology — a platform already in use across clinical sites in
Latin America for the early
detection of diabetic retinopathy, cardiovascular disease, and
other chronic conditions. The move also signals growing confidence
from Avant's leadership as they prepare to bring proprietary
hardware into the mix.
In parallel with the merger discussions, Avant and
Ainnova are entering the final prototyping stage of a
low-cost, automated retinal imaging device — marking a potential
turning point in the companies' shared push toward AI-powered early
diagnostics.
The new device is designed to operate hands-free and feed
imaging data directly into the Vision AI platform, enabling
near-instant risk reports without expensive equipment or trained
personnel.
The companies say the camera, developed under their joint
venture Ai-nova Acquisition Corp. (AAC), is expected to cost
a fraction of legacy fundus cameras. By combining affordability
with automation, the device could expand screening access across
primary care clinics and emerging-market providers that have
traditionally been priced out of ophthalmic diagnostics.
"The cost of a fundus camera has always been a barrier to entry
in this market," said Vargas. "Our low-cost camera, which is a
fraction of the cost of currently available cameras on the market,
should allow us to not only enter the market, but to capture a
large share of the market."
Also in development are additional platform modules, including a
patented dementia detection tool that combines a five-minute blood
test with AI-trained algorithms. Although that technology remains
in evaluation, the core platform continues to expand its reach and
functionality — evolving from a retinal-focused application into a
broader engine for predictive healthcare.
"Our purpose is to create the future of early disease detection
in an accessible way, so that patients can get a preventive
check-up anywhere, at a low cost, and easily," said Vargas in a
previous statement. "We want to prevent patients with risk factors
from developing other diseases that could have been avoided before
they became a real problem. To this end, we are seeking to
integrate new technologies into our portfolio within a single
platform, both through our R&D efforts and through potential
exclusive licenses or acquisitions."
As the camera prototype nears completion, Avant is
positioning itself for broader market entry. While a launch date
has yet to be announced, the integrated platform is designed to
reduce diagnostic friction, speed up referrals, and expand access
to early-stage health insights — especially in geographies where
affordability, not innovation, remains the primary barrier to
care.
CONTINUED... Read this and more news for Avant
Technologies at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Renovaro Inc. (NASDAQ: RENB) recently announced a major
expansion to its intellectual property portfolio with a newly
approved U.S. patent for its AI-powered drug discovery and
diagnostics infrastructure.
"This patent is a strategic milestone for Renovaro," said
David Weinstein, CEO of
Renovaro. "Together with our previously granted patent, it
forms the technological foundation of a scalable, end-to-end
platform for AI-powered drug discovery and diagnostics and
strengthens our position in the fast-growing market for data-driven
therapeutics and clinical insights."
The patent protects methods that harmonize genomic, imaging,
clinical, and health record data into a standardized framework for
large-scale predictive analytics. These capabilities are built for
distributed computing environments, aligning with the biopharma
industry's move toward real-time, scalable analytics. The
development enhances Renovaro's competitive positioning in
data-driven therapeutics and clinical insight markets.
Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) recently
showcased its leadership in AI-driven cancer research at the 2025
ASCO Annual Meeting, where Ruth
Porat discussed Alphabet's evolving role in early
diagnosis and treatment.
"AI has greater potential than the internet, because it can
augment human capabilities," wrote Ruth
Porat, President & Chief Investment Officer of
Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for
each of us."
Porat highlighted Google's success with AlphaFold, which
has accelerated cancer drug discovery by solving the decades-long
problem of protein folding. She also noted the company's
AI-assisted pathology tools that cut diagnostic time in half and
improve detection of small metastases. From scalable diabetic
retinopathy screening to generative AI for clinical workflows, she
framed AI as a transformative force in healthcare delivery.
Omada Health, Inc. (NASDAQ: OMDA) entered the public
markets with a strong debut, raising $150
million and closing its first trading day 21% above IPO
pricing. The company delivers AI-augmented virtual care for chronic
conditions like diabetes, hypertension, and obesity, serving more
than 679,000 active members.
In May, prior to the IPO, Omada introduced Nutritional
Intelligence, a new member experience powered by OmadaSpark—an
AI agent that offers personalized, evidence-based nutrition
coaching between clinical visits. As demand rises for
GLP-1 medications, Omada is positioning its
human-plus-AI model as essential to long-term metabolic health.
"We believe there is a clear market need for real-time
educational support backed by behavioral science to improve
mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health.
"To meet the needs of our customers and members, Omada fine
tuned its approach to offer AI-powered tools trained with clinical
input and expertise to work alongside human care teams in helping
members drive improved health and economic outcomes."
Amazon.com, Inc. (NASDAQ: AMZN) continues to scale
its digital health footprint via Amazon Web Services (AWS),
which recently brought its HealthLake platform to the EU's Dublin
Region. The move enables hospitals and insurers to unify siloed
patient data using FHIR standards, while running AI-driven
analytics and maintaining full data residency compliance.
"I'm excited about AWS HealthLake launch in EU Region," said
Ramon Postulart, CTO at
Adapcare. "AWS HealthLake is a key AWS
healthcare service helping us modernize interoperability across the
70+ care organizations and 60,000 health professionals we support
in the Netherlands. By moving to
this service, we're unlocking richer, standardized health data and
leveraging the HealthLake fully managed capabilities to build
smarter, AI-powered tools for care planning and coordination."
HealthLake now serves as the engine behind personalized care
tools in development across Ireland, the
Netherlands, and Finland.
AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data
innovation and the European Health Data Space initiative.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
CONTACT:
Equity
Insider
info@equity-insider.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Logo -
https://mma.prnewswire.com/media/2644233/5362794/Equity_Insider_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smart-healthcare-is-taking-over-heres-where-the-moneys-headed-302477870.html
SOURCE Equity Insider
